Bevacizumab Lyophilized powder B077-5MG

产品介绍

Bevacizumab is a recombinant humanized monoclonal antibody used in cancer research.  Its development was based on the discovery of human vascular endothelial growth factor (VEGF), a protein that stimulates blood vessel growth.  VEGF was discovered by N Ferrara (Genentech), who later demonstrated that antibodies against VEGF inhibited tumor growth in mice.  It was derived from a mouse monoclonal antibody after immunization with 165-resisdue from VEGF.  It was humanized by keeping the binding region and replacing the rest with a human full light chain and a human tuncated igG1 heavy chain along with additonal substitutions.  The plasmid that resulted was transferred into CHO cells via transfection and grown in a fermenter at industrial scale.  It was the first approved angiogenesis inhibitor in the market (Avastin®)(F Hoffmann La-Roche AG).

It has also been used for ophthalmic research to investigate ocular disease processes.  

Bevacizumab biosimilars include: bevacuzumab-awwb, bevacuzumab-maly, bevacuzumab-adcd, and bevacizumab-tnjn. 

Research has shown that those with COVID-19 have higher VEGF expression which may lead to lung pathology such as acute respiratory syndrome (ARDS) and acute lung injury (ALI), so Bevacizumab is being investigated for lung complications from severe COVID-19.